Alnylam Pharmaceuticals (ALNY) Other financing activities (2018 - 2026)

Alnylam Pharmaceuticals has reported Other financing activities for 8 years, with the latest figure at -$9000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities changed N/A year-over-year to -$9000.0; the trailing twelve-month figure through Mar 2026 stood at -$9000.0 (up 99.71% YoY), and the FY2025 full-year result was $2.4 million, changed N/A from the prior year.
• Other financing activities for Q1 2026 stood at -$9000.0, up from -$1.8 million in the prior quarter.
• The five-year high for Other financing activities was $8.3 million in Q3 2023, with the low at -$16.3 million in Q4 2023.
• Historically, Other financing activities has averaged $2.6 million across 4 years, with a median of $4.0 million in 2023.
• Annual changes were most pronounced in 2022 — Other financing activities jumped 174.97% — and 2023, when it plunged 317.77%.
• Alnylam Pharmaceuticals' Other financing activities stood at $7.5 million in 2022, then sank by 317.77% to -$16.3 million in 2023, then surged by 89.16% to -$1.8 million in 2024, then soared by 99.49% to -$9000.0 in 2026.
• The last three Other financing activities figures came in at -$9000.0 (Q1 2026), -$1.8 million (Q3 2024), and -$1.3 million (Q2 2024), per Business Quant data.